02196 FOSUN PHARMA
- 13.840
- -0.120-0.86%
FOSUN PHARMA News
Shanghai Fosun Pharmaceutical Subsidiary Signs Cooperation, License Deal
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
FOSUN PHARMA (600196.SH) has signed a cooperation and licensing agreement with Palleon, intending to carry out joint clinical research on the licensed product Hanlikang.
FOSUN PHARMA (600196.SH) announced that its controlling subsidiary HENLIUS signed an agreement with Palleon...
FOSUN PHARMA (600196.SH): A subsidiary has signed a licensing agreement.
Gelonghui, December 19 - FOSUN PHARMA (600196.SH) announced that on December 19, 2024, its holding subsidiary HENLIUS signed a "Cooperation and License Agreement" with Palleon. According to the agreement, both parties will collaborate on the global development of Palleon’s investigational product E-602 and related combination therapy solutions within the field (i.e., for the treatment of human diseases) based on their respective patents and proprietary technologies, and will carry out commercialization in their respective licensed areas.
Shanghai Fosun Pharma Moves Hong Kong Office
Regent Pacific's Strategic Partners Submits NDA for Premature Ejaculation Drug in China
Market Cool On Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s (SHSE:600196) Earnings
Hong Kong stocks moved | HENLIUS (02696) opened more than 4% higher, FOSUN PHARMA stated that the prerequisites for the merger with HENLIUS have been met.
HENLIUS (02696) opened over 4% higher, and as of the time of reporting, it increased by 4.72%, trading at 23.3 Hong Kong dollars, with a transaction volume of 2.1972 million Hong Kong dollars.
Shanghai Fosun Pharmaceutical Moves Forward With Henlius Merger
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
Fosun Pharmaceutical Buys Back Nearly 3 Million Yuan Worth of Shares
On December 13, FOSUN PHARMA (02196.HK) spent HKD 2.6635 million to repurchase 0.1855 million shares.
Gelonghui reported on December 13 that FOSUN PHARMA (02196.HK) announced that on December 13, 2024, it would spend 2.6635 million Hong Kong dollars to repurchase 0.1855 million shares, with a repurchase price per share ranging from 14.3 to 14.46 Hong Kong dollars.
Fosun Pharma Boosts Equity in Key Funds
Express News | Shanghai Fosun Pharma - Ningbo Fuying Will Acquire Equity Interests of RMB200.00 of Fund
Shanghai Fosun Pharma's New Strategic Agreements With Fosun International
FOSUN PHARMA (600196.SH): The controlling subsidiary intends to increase its shareholding in the Fund.
On December 11, Gelonghui reported that FOSUN PHARMA (600196.SH) announced that its holding subsidiary Ningbo Fuying, as an LP of the Nanjing Fund, Dalian Star Future Fund, and Suzhou Angel Fund, signed transfer agreements with FOSUN High Technology regarding the Shareholding of several property interests in these funds. The total consideration for this Shareholding is 140.42 million yuan, which includes: (1) a proposed investment of 90.92 million yuan to acquire another LP share of the Nanjing Fund, for which FOSUN High Technology has already contributed 200 million yuan, accounting for about 25.09% of the total contributed amount of this fund (of which 11 million yuan has been paid in).
On December 9, Fosun Pharma (02196.HK) spent 4.36 million Hong Kong dollars to repurchase 306,000 shares.
Gelonghui, December 9th丨Fosun Pharma (02196.HK) announced that on December 9, 2024, it spent 4.36 million Hong Kong dollars to repurchase 0.306 million shares at a price of 14.1-14.5 Hong Kong dollars per share.
Bearish landing? Hong Kong stocks in the pharmaceutical sector collectively strengthen with wuxi apptec rising over 8%.
① How much impact did the biological safety legislation have on domestic pharmaceutical stocks previously? ② How do industry insiders view the subsequent development of the biological legislation?
Hong Kong stock concept tracking | The biocontrol bill was not included in the latest version of NDAA. Institutions are bullish on the bottom opportunities in the CXO sector (with concept stocks attached).
On December 7, 2024, local time in the USA, the US Congressional Armed Services Committees in both the House and the Senate released the final agreement text of the 2025 National Defense Authorization Act (NDAA), which incorporates proposals from both chambers.
Honkong stock market movement | CRO concept stocks collectively opened higher as the bioprotective legislation was not included in the final version of the NDAA by the U.S. Senate and House of Representatives.
CRO concept stocks opened higher collectively. As of the time of writing, wuxi bio (02269) increased by 13.03%, trading at 19.6 Hong Kong dollars; wuxi apptec (02359) rose by 11.72%, trading at 61 Hong Kong dollars; pharmaron (03759) climbed by 9.14%, trading at 16 Hong Kong dollars.
No Data
